FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmacology and medicine and aims at treating acute respiratory distress syndrome (ARDS). Method of treating ARDS involves administering effective amounts of a pulmonary surfactant and a hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH (I) or a pharmaceutically acceptable salt thereof into a mammal in need thereof.
EFFECT: use of the invention enables higher clinical effectiveness in ARDS by combined use of a pulmonary surfactant and a hexapeptide of formula (I), which synergistically effectively reduces the risk of ARDS mortality.
1 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
| USE OF DALARGIN FOR PRODUCTION OF DRUG PREPARATIONS FOR PREVENTING PNEUMONIA | 2020 |
|
RU2728938C1 |
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
| APPLICATION OF AN ALPHA1-PROTEINASE INHIBITOR (ALPHA1-ANTITRYPSIN) FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND METHOD FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME USING ALPHA1-ANTITRYPSIN | 2020 |
|
RU2757875C1 |
| USE OF HEXAPEPTIDE TO REDUCE LEVELS OF EXTRACELLULAR HMGB1 PROTEIN IN INFLAMMATORY DISEASES | 2021 |
|
RU2813878C2 |
